[Treatment of leprosy by human metabolites].
We are interested for other human metabolites than desoxyfructo-serotonin (DFS), showing antileprosy activity. This is the case of desoxyfructo-5-hydroxytryptophan and of some liposoluble derivatives of DFS. The time of resorption and penetration into M. leprae infected tissue, is very different for these metabolites. For this reason the simultaneous application of these compounds may represent some advantage in the treatment of multibacillar form of leprosy. The use of DFS together with the antileprosy diet "NAL" have the supplementary advantage to stabilize the DFS level in the serum during the treatment.
D006916:5-Hydroxytryptophan / Q000031:analogs & derivatives* / Q000378:metabolism / Q000627:therapeutic use; D000818:Animals; D006031:Glycosylation; D006801:Humans; D007917:Leprostatic Agents; D007918:Leprosy / Q000188:drug therapy*; D007980:Levodopa / Q000031:analogs & derivatives / Q000627:therapeutic use; D051379:Mice; D014442:Monophenol Monooxygenase / Q000037:antagonists & inhibitors; D012701:Serotonin / Q000031:analogs & derivatives* / Q000378:metabolism / Q000627:therapeutic use / Q000633:toxicity; D014364:Tryptophan / Q000031:analogs & derivatives
D007917:Leprostatic Agents; C051992:desoxyfructo-5-hydroxytryptophan; D012701:Serotonin; D007980:Levodopa; C018901:desoxyfructo-serotonin; C051991:desoxyfructo-L-DOPA; D014364:Tryptophan; D006916:5-Hydroxytryptophan; D014442:Monophenol Monooxygenase
Traitement de la lèpre par des métabolites humaines.